Hormone replacement therapy for the critically ill

Critical Care Medicine

Volumn 31, Issue 2, 2003, Pages 634-635

  Annane, Djillali ^a   Melchior, Jean Claude ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Counter regulatory hormones; Critical illness; Energetic substrate; Glucose metabolism; Insulin

Indexed keywords

GLUCOSE; HYDROCORTISONE; INSULIN; RECOMBINANT GROWTH HORMONE; VASOPRESSIN;

ACUTE DISEASE; ADRENAL INSUFFICIENCY; CRITICAL ILLNESS; DIABETES MELLITUS; EDITORIAL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; INTENSIVE CARE UNIT; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT INDICATION; VASODILATATION;

CRITICAL ILLNESS; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN;

EID: 0037323838     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000045569.14948.F2     Document Type: Editorial

References (21)

1. O'Riordain MG, Ross JA, Fearon KCH, et al: Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol 1995; 269:E323-E330
2. Tappy L, Schwarz JM, Schneiter P, et al: Effects of isoenergetic glucose-based or lipid-based parenteral nutrition on glucose metabolism, de novo lipogenesis, and respiratory gas exchanges in critically ill patients. Crit Care Med 1998; 26:860-867
3. Sheatam B, Kahn CR: Insulin action and insulin signalling network. Endocrinol Rev 1995; 16:117-142
4. Chiolero R, RevelIy JP, Tappy L: Energy metabolism in sepsis and injury. Nutrition 1997; 13:45S-51S
5. Norhammar AM, Ryden L, Malmbert K: Admission plasma glucose: Independent risk factor for long term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 1999; 22:1827-1831
6. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
7. Van den Berghe G, Wouters PJ, Bouillon R, et al: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31:359-366
8. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287:2563-2569
9. Rassias AJ, Marrin CA, Arruda J, et al: Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999; 88:1011-1016
10. Saltiel AR, Kahn R: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799-806
11. Shimomura I, Hammer RE, Ikemoto S, et al: Leptin reverses insulin resistance and diabetes in mice with congenital lipodystrophy. Nature 1999; 401:73-76
12. Soop M, Duxbury H, Agwunobi AO, et al: Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab 2002; 282:E1276-E285
13. Kotani K, Yonezawa K, Hara K, et al: Involvement of phosphoinositide 3-kinase in insulin- or IGF-1-induced membrane ruffling. EMBO J 1994; 13:2313-2321
14. Zigmond SH: Signal transduction and actin filament organization. Curr Opin Cell Biol 1996; 8:66-73
15. Van den Berghe G: Pituitary function in the critically ill. Int Growth Monitor 2000; 10:2-7
16. Takala J, Ruokonen E, Webster NR, et al: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792
17. Paton NI, Newton PJ, Sharpstone DR, et al: Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS 1999; 13:1195-1202
18. Bone RC, Fisher CJ Jr, Clemmer TP, et al: A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658
19. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
20. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595
21. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209-1210